Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03513328
Recruitment Status : Recruiting
First Posted : May 1, 2018
Last Update Posted : May 21, 2019
Sponsor:
Collaborator:
Live Like Bella Pediatric Cancer Research
Information provided by (Responsible Party):
University of Florida

Tracking Information
First Submitted Date  ICMJE April 19, 2018
First Posted Date  ICMJE May 1, 2018
Last Update Posted Date May 21, 2019
Actual Study Start Date  ICMJE June 15, 2018
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 19, 2018)
Assessment of minimum effective dose (MED) of Thiotepa [ Time Frame: Day 42 ]
Assess the MED of thiotepa in combination with reduced-dose busulfan, fludarabine and rATG required to achieve engraftment in >90% subjects undergoing hematopoietic stem cell transplantation for non-malignant disorders.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03513328 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: May 15, 2018)
  • Evaluation of risk of graft rejection/failure. [ Time Frame: Day 42; Day 365 ]
    Change in confidence interval (CI) of all subjects who initiated conditioning regimen and have sustained engraftment failure.
  • Evaluation of disease free survival (DFS) [ Time Frame: Month 12; Month 24 ]
    Change in confidence interval (CI) of all subjects who initiated conditioning regimen and are without evidence of underlying disease (DFS).
  • Evaluation of overall survival (OS) [ Time Frame: Month 12; Month 24 ]
    Change in confidence interval (CI) of all subjects who initiated conditioning regimen and are alive (OS).
  • Evaluation of transplant-related mortality [ Time Frame: Day 100; Month 12 ]
    Change in CI of subjects who initiated conditioning regimen and who die due to a cause unrelated to the underlying disease.
  • Rate of acute graft-versus-host disease (GVDH) scale [ Time Frame: Month 12 ]
    Rank of Modified Glucksberg Staging Criteria. (Scale 0-4; with 4 being most severe)
  • Rate of chronic graft-versus-host disease (cGVHD) scale [ Time Frame: Month 24 ]
    Rank of cGVHD grading. (Scale mild, moderate, severe)
  • Change in transplant-related complications [ Time Frame: Month 12; Month 24 ]
    Complications gathered via CIBMTR (Center for International Blood & Marrow Transplant Research) post-transplant form will be tabulated and described by treatment received.
Original Secondary Outcome Measures  ICMJE
 (submitted: April 19, 2018)
  • Evaluation of risk of graft rejection/failure. [ Time Frame: Day 42; Day 365 ]
    Proportion and associated confidence interval (CI) of all subjects who initiated conditioning regimen and have sustained engraftment failure.
  • Evaluation of disease free survival (DFS) [ Time Frame: Month 12; Month 24 ]
    Proportion and associated confidence interval (CI) of all subjects who initiated conditioning regimen and are without evidence of underlying disease (DFS).
  • Evaluation of overall survival (OS) [ Time Frame: Month 12; Month 24 ]
    Proportion and associated confidence interval (CI) of all subjects who initiated conditioning regimen and are alive (OS).
  • Evaluation of transplant-related mortality [ Time Frame: Day 100; Month 12 ]
    Proportion and associated CI of subjects who initiated conditioning regimen and who die due to a cause unrelated to the underlying disease.
  • Rate of acute graft-versus-host disease (GVDH) scale [ Time Frame: Month 12 ]
    Rank of Modified Glucksberg Staging Criteria. (Scale 0-4; with 4 being most severe)
  • Rate of chronic graft-versus-host disease (cGVHD) scale [ Time Frame: Month 24 ]
    Rank of cGVHD grading. (Scale mild, moderate, severe)
  • Change in transplant-related complications [ Time Frame: Month 12; Month 24 ]
    Complications gathered via CIBMTR (Center for International Blood & Marrow Transplant Research) post-transplant form will be tabulated and described by treatment received.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Official Title  ICMJE PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders
Brief Summary In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum effective dose required for reliable engraftment for subjects undergoing hematopoietic stem cell transplantation for non-malignant disease.
Detailed Description Hematopoietic stem cell transplantation is the only curative choice for a number of inherited bone marrow failure syndromes, hemoglobinopathies, metabolic disorders and primary immune deficiencies. While survival of these patients is typically better than survival of patients with malignancies, toxicities of conditioning regimens and failure of engraftment remain challenges. Most children with non-malignant disorders present with normocellular or even hypercellular bone marrow, posing a barrier to engraftment and requiring intensive conditioning. Commonly used backbone of busulfan and fludarabine, although well tolerated, results in variable engraftment, in particular with mismatched unrelated donors and cord blood recipients. In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) in order to determine the minimum effective dose required for reliable engraftment. Subjects are stratified in groups A and B based the risk of graft failure.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The study builds in rules for escalation of thiotepa dose based on graft failure by day 42. Patients are stratified in two groups A (lower risk of graft failure) and B (higher risk of graft failure). Patients undergoing 10/10 HLA matched bone marrow and peripheral blood transplants are assigned to Group A, and patients receiving <10/10 matched bone marrow or peripheral blood, or receiving cord blood, even if fully matched, are assigned to Group B.

If criteria for thiotepa dose escalation are met first in Group A, which has a lower risk of graft failure, thiotepa dose will be escalated for all subjects (Groups A and B). If criteria for thiotepa dose escalation are met first in Group B, dose will be escalated only in Group B and Group A will continue enrolling patients at a lower dose level.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Bone Marrow Failure Syndrome
  • Thalassemia
  • Sickle Cell Disease
  • Diamond Blackfan Anemia
  • Acquired Neutropenia in Newborn
  • Acquired Anemia Hemolytic
  • Acquired Thrombocytopenia
  • Hemophagocytic Lymphohistiocytoses
  • Wiskott-Aldrich Syndrome
  • Chronic Granulomatous Disease
  • Common Variable Immunodeficiency
  • X-linked Lymphoproliferative Disease
  • Severe Combined Immunodeficiency
  • Hurler Syndrome
  • Mannosidosis
  • Adrenoleukodystrophy
Intervention  ICMJE
  • Drug: Thiotepa--single daily dose
    Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
  • Drug: Thiotepa--escalated dose
    Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Study Arms  ICMJE
  • Experimental: Group A--Thiotepa single dose
    Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
    Intervention: Drug: Thiotepa--single daily dose
  • Experimental: Group A--Thiotepa escalated dose
    Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
    Intervention: Drug: Thiotepa--escalated dose
  • Active Comparator: Group B--Thiotepa single dose
    Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
    Intervention: Drug: Thiotepa--single daily dose
  • Active Comparator: Group B--Thiotepa escalated dose
    Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
    Intervention: Drug: Thiotepa--escalated dose
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 19, 2018)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2022
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnoses:

    • Hemoglobinopathies (e.g. thalassemia or sickle cell disease),
    • Cytopenias (e.g.Diamond-Blackfan anemia, congenital or acquired neutropenia, congenital or acquired thrombocytopenia, congenital or acquired anemia, and others, regardless clonality),
    • Hemophagocytic lymphohistiocytosis,
    • Primary immunodeficiencies (e.g. Wiscott Aldrich Syndrome, chronic granulomatous disease, common variable immune deficiency, X-linked lymphoproliferative disease, NK+ severe combined immune deficiencies),
    • Metabolic disorders (Hurler's syndrome, mannosidosis, adrenal leuko-dystrophy)
    • Other non-malignant disorders for which there is published evidence that HSCT (hematopoietic stem cell transplant) is a curative therapy.
  • Donor Requirements

    • Related or unrelated donor who is suitable and willing to donate bone marrow or peripheral blood stem cells. HLA typing should be done by high-resolution typing at A, B, C, DrB1 and DQ loci and the donor should be at a minimum ≥8/10 match (with one antigen/allele mismatch allowed at A, B, or C-loci and other at DQ loci).
    • Cord blood units must be matched at a minimum of 6/8 antigens/alleles at A, B, C and DrB1 loci. High resolution typing at all loci is required. The minimum TNC dose pre-cryopreservation must be ≥3.7 x10^7/kg of recipient's weight, if a single cord blood unit is used, or at least 2x10^7/kg per unit, if two cord blood units are used. The mismatches cannot be at the same loci (e.g. double A mismatch).
    • Haploidentical related stem cell donor who is suitable and willing to donate peripheral blood stem cells. T-cell depletion is required if haploidentical donors are used. Pharmacologic GVHD prophylaxis will not be used for T-cell depleted transplant recipients.
  • Adequate organ function defined as:

    • Cardiac: ejection fraction ≥55% or shortening fraction ≥30%
    • creatinine clearance ≥70 ml/min/1.73m2
    • Pulse oximetry >95% on room air or FEV1/DLCO >60%
    • LFTs < 3 x ULN, Total bilirubin <3 mg/dl (unless due to non-hepatic cause (e.g. Gilbert's syndrome or hemolysis)
  • Lansky/Karnofsky score ≥60%
  • Written informed consent obtained from the subject or parental/guardian permission ± child's assent per institutional guidelines
  • Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy for at least 1 month after completion of conditioning. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:

    • Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or
    • For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.
    • Males with female partners of childbearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, or vasectomy) for at least one month after completion of conditioning.

Exclusion Criteria:

  • Diagnoses that do not require myeloablative transplant for cure (e.g. NK- SCID patients), unless the subject previously did not engraft with non-myeloablative or reduced intensity conditioning transplant.
  • Known or suspected sensitivity to chemotherapy or radiation (e.g Fanconi's anemia, Dyskeratosis congenita, Ligase IV deficiency, etc).
  • Subjects with fast-progressing neurodegenerative disorders (e.g. Krabbe disease or adrenal leukodystrophy with Loes score of ≥10)
  • Cytopenias with increased blasts (>5%)
  • Presence of anti-donor HLA antibodies (positive anti-donor HLA antibody is defined as a positive cross-match test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) or the presence of anti-donor HLA antibody to the high expression loci HLA-A, B, C, DRB1 with mean fluorescence intensity (MFI)>3000 by solid phase
  • Prior allogeneic stem cell transplant, except for patients with immune deficiencies who underwent previous non-myeloablative or reduced intensity transplants.
  • Haploidentical donor using in vivo T-cell depletion (e.g. post-transplant cyclophosphamide).
  • Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment.
  • Seropositive for HIV
  • Active Hepatitis B or C determined by a detectable viral load of HBV or HCV by PCR
  • Bridging fibrosis or liver cirrhosis
  • Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 1 months after the end of conditioning
  • Females who are pregnant or breastfeeding
  • History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
  • Subjects demonstrating an inability to understand the study and comply with the study and/or follow-up procedures
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Months to 38 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Giselle Moore-Higgs, PhD 3522739050 mooregj@ufl.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03513328
Other Study ID Numbers  ICMJE IRB201800798
PEDS024 ( Other Identifier: UF Health )
OCR17838 ( Other Identifier: Universiy of Florida )
AWD05935 ( Other Grant/Funding Number: Live Like Bella Pediatric Cancer Research )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: There is no plan at this time.
Responsible Party University of Florida
Study Sponsor  ICMJE University of Florida
Collaborators  ICMJE Live Like Bella Pediatric Cancer Research
Investigators  ICMJE
Principal Investigator: Biljana Horn, MD University of Florida
PRS Account University of Florida
Verification Date May 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP